EXTON, Pa.--(BUSINESS WIRE)--April 21, 2006--Antares Pharma, Inc. (Amex:AIS - News) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review its licensee's (BioSante Pharmaceuticals, Inc.), New Drug Application (NDA) for transdermal estradiol gel (Bio-E-Gel®). The NDA includes data from a Phase III clinical trial as well as data from a sunscreen study, a pharmacokinetic study and a transfer study.
